This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
Events & Webinars

BNMS 2024

In the PSMA era, is there still a place for Xofigo▼ (radium-223 dichloride) in the management of advanced prostate cancer?

Xofigo Header Image

An on demand video of the Bayer-sponsored symposium at the British Nuclear Medicine Society (BNMS) Spring Meeting 2024, which took place in Belfast on the 15th May 2024. In this session

Professor Joe O'Sullivan
, Clinical Oncologist, Northern Ireland Cancer Centre articulates the potential impact of radionuclide therapies on managing prostate cancer, with a specific focus on radium-223.

This symposium was organised and funded by Bayer.

Xofigo
▼
Prescribing Information

NUBEQA
®
(darolutamide) Prescribing Information

Speakers

Evolving mCRPC treatment landscape in 2023
Xofigo®▼ (radium-223 dichloride)
PP-XOF-GB-0505, February2024

Abbreviations: PSMA
; prostate-specific membrane antigen

 

PP-XOF-GB-0598 | January 2025